# QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer

> **NCT06917092** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Endometrial Adenocarcinoma
- Endometrial Cancer

## Interventions

- **DRUG:** QL1706 combined with chemotherapy ± Bevacizumab

## Key facts

- **NCT ID:** NCT06917092
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2027-04-30
- **Final completion:** 2030-04-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06917092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06917092, "QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06917092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*